Keliximab

Keliximab (SB-210396) is a chimeric human/macaque IgG1 anti-CD4 monoclonal antibody with a Ki value of 1.0 nM for soluble CD4. Keliximab blocks T cell proliferation and inhibits IL-2 production. Keliximab can be used for cancer research[1][2].

Product Specifications

CAS Number

[174722-30-6]

Product Name Alternative

SB-210396; IDEC CE9.1

UNSPSC

12352203

Target

Interleukin Related

Type

Inhibitory Antibodies

Related Pathways

Immunology/Inflammation

Applications

Cancer-programmed cell death

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/keliximab.html

Purity

98.23

Solubility

10 mM in DMSO

Smiles

[Keliximab]

Molecular Weight

(144.12 kDa)

References & Citations

[1]Sharma A, et al. Comparative pharmacodynamics of keliximab and clenoliximab in transgenic mice bearing human CD4. J Pharmacol Exp Ther. 2000 Apr;293 (1) :33-41.|[2]Anderson D, et al. A primatized MAb to human CD4 causes receptor modulation, without marked reduction in CD4+ T cells in chimpanzees: in vitro and in vivo characterization of a MAb (IDEC-CE9.1) to human CD4. Clin Immunol Immunopathol. 1997 Jul;84 (1) :73-84.